4/11
08:06 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $66.00 price target on the stock.
4/8
12:00 pm
mrus
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
Low
Report
Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024
4/3
08:00 am
mrus
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
3/28
08:26 am
mrus
Merus (NASDAQ: MRUS) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $69.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) is now covered by analysts at Truist Financial Co.. They set a "buy" rating and a $69.00 price target on the stock.
3/5
04:30 pm
mrus
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
Low
Report
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
3/4
11:05 pm
mrus
Merus (NASDAQ: MRUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Merus (NASDAQ: MRUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
3/4
08:06 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Needham & Company LLC from $42.00 to $65.00. They now have a "buy" rating on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Needham & Company LLC from $42.00 to $65.00. They now have a "buy" rating on the stock.
3/4
08:00 am
mrus
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
Medium
Report
Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference
2/29
03:42 pm
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at HC Wainwright from $48.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at HC Wainwright from $48.00 to $65.00. They now have a "buy" rating on the stock.
2/29
01:32 pm
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Stifel Nicolaus from $40.00 to $65.00. They now have a "buy" rating on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Stifel Nicolaus from $40.00 to $65.00. They now have a "buy" rating on the stock.
2/29
08:16 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at BMO Capital Markets from $49.00 to $58.00. They now have an "outperform" rating on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at BMO Capital Markets from $49.00 to $58.00. They now have an "outperform" rating on the stock.
2/28
04:15 pm
mrus
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
Low
Report
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update
1/31
08:00 am
mrus
Merus to Participate in Upcoming Investor Conferences
Medium
Report
Merus to Participate in Upcoming Investor Conferences